An announcement has been made by Daiichi Sankyo UK that the first three-in-one bill (Sevikar HCT) to treat hypertension ( high blood pressure ) has been launched. In the UK, approximately 8.5 million individuals are affected with hypertension. As symptoms are rarely clear, the condition is known as the "silent killer." Hypertension is the most prevalent cause of stroke if left untreated or unmanaged. Nearly 2 million people in the UK currently take three or more pills in order to treat their condition, although 80% do not take their pills as directed by their doctor, or throw them away. If patients suffering with hypertension take their medication as directed by their doctor it is significantly easier to control. The new 3-in-1 pill reduces the number of medications patients with hypertension need to take.
Atrial Fibrillation patients who are prescribed the powerful blood thinner warfarin often take it with vitamins or supplements that can hamper its effectiveness, or skip doses completely, increasing their risk for stroke, according to new research. The study, jointly conducted by researchers at the Intermountain Medical Center Heart Institute and registered dieticians from Utah State University, also suggests these same patients don't know much about this powerful blood thinner and why they need to take it as directed. Results were presented at the American Heart Association Scientific Sessions in Orlando, Fla. To learn how patients comply with their warfarin prescriptions, researchers administered a 52-item questionnaire to 100 randomly recruited Heart Institute patients previously diagnosed with atrial fibrillation.
Eliminating Co-Payments For Heart Attack Medications Increases Adherence And Reduces Major Vascular Events
The use of specific medications following a heart attack has been shown to reduce cardiovascular events and mortality, however; while highly effective, the rate of adherence to these medications is poor. Researchers from Brigham and Women's Hospital (BWH) evaluated whether eliminating co-payments for these medications would increase adherence and improve outcomes in patients who have had a heart attack. They were presented as a Late Breaking Clinical Trial at the American Heart Association Scientific Sessions on November 14 and simultaneously published online in the New England Journal of Medicine. "The elimination of co-payments for certain medications following a heart attack resulted in improved patient adherence to the medications and positively impacted rates of major vascular events, " said Niteesh Choudhry, MD, PhD, lead author of the paper and a researcher in the Division of Pharmacoepidemiology and Pharmacoeconomics at BWH as well as an Associate Professor of Medicine at Harvard Medical School.
Eliminating co-payments is better for patients who have had a heart attack; their outcomes are better, they are more likely to adhere to their treatment regime, and costs are lower, researchers from Brigham and Women's Hospital and Harvard Medical School revealed today in NEJM (New England Journal of Medicine as well as the American Heart Association Scientific Sessions. Although drugs can reduce the risk of subsequent cardiovascular events for heart attack patients, adherence rates are generally poor. Adherence is the process in which a patient follows his/her doctor's instructions, including when to take certain medications. In this study, the researchers set out to determine whether eliminating co-payments for post-heart attack medications might improve adherence and provide better outcomes.
Patients being treated for chronic hepatitis C become less likely to take their medications over time, according to a new study from the Perelman School of Medicine at the University of Pennsylvania. Since the study also showed better response to the drugs when they're taken correctly, the researchers say the findings should prompt clinicians to assess patients for barriers to medication adherence throughout their treatment, and develop strategies to help them stay on track. The study is published online this month in Annals of Internal Medicine. "Our findings are particularly timely since many chronic hepatitis C patients are now being prescribed direct-acting antiviral drugs, which have a complex dosing regimen that may be even harder for patients to maintain than the two-drug standard therapy, " said lead author Vincent Lo Re, MD, MSCE, an assistant professor of Infectious Disease and Epidemiology.